Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125314232 | 12531423 | 2 | F | 2012 | 20151001 | 20160706 | 20160719 | PER | US-MALLINCKRODT-T201504656 | MALLINCKRODT | 0.00 | F | Y | 78.00000 | KG | 20160719 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125314232 | 12531423 | 1 | PS | FENTANYL TRANSDERMAL SYSTEM | FENTANYL | 1 | Transdermal | 50 MCG/HR, ONE Q72H | Y | UNKNOWN | 77154 | TRANSDERMAL PATCH | |||||||
| 125314232 | 12531423 | 2 | SS | FENTANYL TRANSDERMAL SYSTEM | FENTANYL | 1 | Transdermal | 25 MCG/HR, ONE Q72H | Y | 5036125B | 77154 | TRANSDERMAL PATCH | |||||||
| 125314232 | 12531423 | 3 | SS | Morphine | MORPHINE | 1 | Oral | UNK | Y | UNKNOWN | 0 | EXTENDED RELEASE TABLET | |||||||
| 125314232 | 12531423 | 4 | SS | Oxycodone | OXYCODONE | 1 | Oral | UNK | Y | UNKNOWN | 0 | TABLET | |||||||
| 125314232 | 12531423 | 5 | C | ALLEGRA | FEXOFENADINE HYDROCHLORIDE | 1 | 180 MG | 0 | |||||||||||
| 125314232 | 12531423 | 6 | C | LEVOTHYROXINE. | LEVOTHYROXINE | 1 | 50 MCG | 0 | |||||||||||
| 125314232 | 12531423 | 7 | C | RANITIDINE. | RANITIDINE | 1 | 150 MG | 0 | |||||||||||
| 125314232 | 12531423 | 8 | C | FLONASE | FLUTICASONE PROPIONATE | 1 | 0 | ||||||||||||
| 125314232 | 12531423 | 9 | C | ASPIRIN. | ASPIRIN | 1 | 81 MG | 0 | |||||||||||
| 125314232 | 12531423 | 10 | C | VITAMIN D | CHOLECALCIFEROL | 1 | 5000 UNITS | 0 | |||||||||||
| 125314232 | 12531423 | 11 | C | TYLENOL | ACETAMINOPHEN | 1 | 3000 MG, QD | 0 | 3000 | MG | QD | ||||||||
| 125314232 | 12531423 | 12 | C | ATENOLOL. | ATENOLOL | 1 | 50 MG | 0 | |||||||||||
| 125314232 | 12531423 | 13 | C | LISINOPRIL. | LISINOPRIL | 1 | 5 MG | 0 | |||||||||||
| 125314232 | 12531423 | 14 | C | ESCITALOPRAM | ESCITALOPRAM OXALATE | 1 | 10 MG | 0 | |||||||||||
| 125314232 | 12531423 | 15 | C | TRAZODONE | TRAZODONE HYDROCHLORIDE | 1 | 50 MG | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125314232 | 12531423 | 1 | Pain |
| 125314232 | 12531423 | 3 | Pain |
| 125314232 | 12531423 | 4 | Pain |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125314232 | 12531423 | Constipation | |
| 125314232 | 12531423 | Drug effect decreased | |
| 125314232 | 12531423 | Hyperhidrosis | |
| 125314232 | 12531423 | Medication residue present | |
| 125314232 | 12531423 | Memory impairment | |
| 125314232 | 12531423 | Product adhesion issue |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125314232 | 12531423 | 1 | 2015 | 201508 | 0 | |
| 125314232 | 12531423 | 2 | 201508 | 0 | ||
| 125314232 | 12531423 | 3 | 2012 | 201504 | 0 | |
| 125314232 | 12531423 | 4 | 2012 | 201504 | 0 |